Citigroup’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-21,000
| Closed | -$561K | – | 5895 |
|
|
2025
Q4 | $561K | Buy |
+21,000
| New | +$502K | ﹤0.01% | 3517 |
|
|
2025
Q3 | – | Sell |
-59,900
| Closed | -$1.29M | – | 6051 |
|
|
2025
Q2 | $1.29M | Buy |
59,900
+30,000
| +100% | +$558K | ﹤0.01% | 3011 |
|
|
2025
Q1 | $497K | Buy |
+29,900
| New | +$543K | ﹤0.01% | 3681 |
|
|
2024
Q1 | – | Sell |
-27,300
| Closed | -$855K | – | 5611 |
|
|
2023
Q4 | $855K | Buy |
+27,300
| New | +$652K | ﹤0.01% | 2959 |
|
|
2023
Q2 | – | Sell |
-49,800
| Closed | -$937K | – | 5554 |
|
|
2023
Q1 | $937K | Buy |
49,800
+19,800
| +66% | +$377K | ﹤0.01% | 2609 |
|
|
2022
Q4 | $478K | Buy |
+30,000
| New | +$469K | ﹤0.01% | 3210 |
|
|
2022
Q3 | – | Sell |
-25,000
| Closed | -$352K | – | 5771 |
|
|
2022
Q2 | $352K | Sell |
25,000
-43,100
| -63% | -$804K | ﹤0.01% | 3481 |
|
|
2022
Q1 | $1.65M | Buy |
+68,100
| New | +$1.65M | ﹤0.01% | 2521 |
|
|
2021
Q1 | – | Sell |
-36,800
| Closed | -$1.97M | – | 6154 |
|
|
2020
Q4 | $1.97M | Buy |
36,800
+15,200
| +70% | +$755K | ﹤0.01% | 2873 |
|
|
2020
Q3 | $891K | Sell |
21,600
-200
| -0.9% | -$8.64K | ﹤0.01% | 3379 |
|
|
2020
Q2 | $1.06M | Buy |
21,800
+4,600
| +27% | +$221K | ﹤0.01% | 3505 |
|
|
2020
Q1 | $727K | Sell |
17,200
-28,600
| -62% | -$1.18M | ﹤0.01% | 3508 |
|
|
2019
Q4 | $1.96M | Buy |
45,800
+6,300
| +16% | +$274K | ﹤0.01% | 3002 |
|
|
2019
Q3 | $1.42M | Buy |
39,500
+20,300
| +106% | +$616K | ﹤0.01% | 3248 |
|
|
2019
Q2 | $513K | Sell |
19,200
-48,600
| -72% | -$1.24M | ﹤0.01% | 4401 |
|
|
2019
Q1 | $1.82M | Buy |
67,800
+26,000
| +62% | +$607K | ﹤0.01% | 2748 |
|
|
2018
Q4 | $676K | Sell |
41,800
-2,600
| -6% | -$50.5K | ﹤0.01% | 3803 |
|
|
2018
Q3 | $922K | Sell |
44,400
-1,000
| -2% | -$15.7K | ﹤0.01% | 3585 |
|
|
2018
Q2 | $693K | Buy |
45,400
+3,600
| +9% | +$64.2K | ﹤0.01% | 3744 |
|
|
2018
Q1 | $939K | Sell |
41,800
-15,100
| -27% | -$418K | ﹤0.01% | 3300 |
|
|
2017
Q4 | $1.71M | Buy |
56,900
+12,800
| +29% | +$409K | ﹤0.01% | 2830 |
|
|
2017
Q3 | $1.66M | Sell |
44,100
-20,700
| -32% | -$673K | ﹤0.01% | 2863 |
|
|
2017
Q2 | $1.81M | Buy |
64,800
+700
| +1% | +$20.9K | ﹤0.01% | 2692 |
|
|
2017
Q1 | $2.2M | Sell |
64,100
-32,800
| -34% | -$1.16M | ﹤0.01% | 2386 |
|
|
2016
Q4 | $2.79M | Buy |
96,900
+52,700
| +119% | +$1.39M | ﹤0.01% | 2541 |
|
|
2016
Q3 | $1.41M | Buy |
44,200
+8,200
| +23% | +$278K | ﹤0.01% | 2861 |
|
|
2016
Q2 | $1.17M | Sell |
36,000
-51,100
| -59% | -$1.71M | ﹤0.01% | 2801 |
|
|
2016
Q1 | $2.44M | Buy |
87,100
+44,900
| +106% | +$979K | ﹤0.01% | 2276 |
|
|
2015
Q4 | $1.5M | Buy |
42,200
+1,700
| +4% | +$59.9K | ﹤0.01% | 2716 |
|
|
2015
Q3 | $1.34M | Buy |
40,500
+24,100
| +147% | +$1M | ﹤0.01% | 2802 |
|
|
2015
Q2 | $687K | Buy |
+16,400
| New | +$635K | ﹤0.01% | 3423 |
|
|
2014
Q2 | – | Sell |
-10,000
| Closed | -$243K | – | 7090 |
|
|
2014
Q1 | $243K | Buy |
+10,000
| New | +$253K | ﹤0.01% | 4147 |
|
Other funds holding ACAD
BBA
VPM
RI
VCM
PAI
Citigroup's ACAD Position: Q1 2026 in Review
Citigroup reduced its Acadia Pharmaceuticals (ACAD) stake by 19% in Q1 2026, selling an estimated $387K and leaving 67,487 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2852.
Citigroup first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. The position peaked at $36M in Q2 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.
- Citigroup held 67,487 shares of Acadia Pharmaceuticals worth $1.5M as of Q1 2026.
- Citigroup sold 16,197 Acadia Pharmaceuticals shares in Q1 2026, an estimated $387K.
- Acadia Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2852 holding.
- Citigroup first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Acadia Pharmaceuticals position peaked at $36M in Q2 2025.
- 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.